NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $16.90 -1.10 (-6.11%) As of 06/26/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendSEC FilingsSustainabilityTrendsBuy This Stock About Crescent Biopharma Stock (NASDAQ:CBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$15.51▼$18.8950-Day Range N/A52-Week Range$11.06▼$63.00Volume109,227 shsAverage Volume64,475 shsMarket Capitalization$10.99 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingStrong Buy Company OverviewCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Read More… Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 390th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingCrescent Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.67, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCrescent Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. Sustainability and ESG3.7 / 5Environmental Score-0.84 Short InterestThere is no current short interest data available for CBIO. News and Social Media2.5 / 5News Sentiment0.50 News SentimentCrescent Biopharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.Search Interest2 people have searched for CBIO on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Crescent Biopharma is held by insiders.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CBIO Stock News HeadlinesStifel Nicolaus Begins Coverage on Crescent Biopharma (NASDAQ:CBIO)June 27 at 2:29 AM | americanbankingnews.comCrescent Biopharma Inc. CBIO Company Vitals - U.S. NewsJune 26 at 10:16 PM | money.usnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 27 at 2:00 AM | Porter & Company (Ad)Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy RecommendationJune 26 at 10:16 PM | msn.comGlycoMimetics (NASDAQ:CBIO) Stock Rating Upgraded by Lifesci CapitalJune 20, 2025 | americanbankingnews.comCatalyst Biosciences, Inc. (CBIO)June 17, 2025 | finance.yahoo.comCrescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 MillionJune 16, 2025 | globenewswire.comCatalyst Biosciences Inc trading halted, volatility trading pauseMarch 19, 2025 | markets.businessinsider.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $15.7950 on January 1st, 2025. Since then, CBIO stock has increased by 7.0% and is now trading at $16.90. View the best growth stocks for 2025 here. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) EPS for the quarter, meeting the consensus estimate of ($7.00). When did Crescent Biopharma's stock split? Crescent Biopharma shares reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/17/2023Today6/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone617-465-0586Fax336-480-2107Employees26Year Founded2003Price Target and Rating Average Stock Price Target$25.00 High Stock Price Target$28.00 Low Stock Price Target$22.00 Potential Upside/Downside+47.9%Consensus RatingStrong Buy Rating Score (0-4)3.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($46.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax Margin-397,340.00% Return on Equity-293.92% Return on Assets-206.20% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.29 Sales & Book Value Annual Sales$10 thousand Price / Sales1,098.50 Cash FlowN/A Price / Cash FlowN/A Book Value$8.24 per share Price / Book2.05Miscellaneous Outstanding Shares650,000Free Float619,000Market Cap$10.99 million OptionableNo Data Beta1.62 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CBIO) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.